Skip to main content
Fig. 2 | Cancer & Metabolism

Fig. 2

From: Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors

Fig. 2

Time-dependent ROC curve analysis for predicting recurrence-free survival in patients with localized primary GIST. According to the modified NIH criteria, SUVmax, MTV, and TLG. All variables are adjusted with regard to adjuvant imatinib treatment. SUV, standard uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; ROC, receiver operating characteristics

Back to article page